Where are we going today with BRS and DES? J. Wykrykowska leads us through two-year results of this all-comer trial comparing ABSORB BRS with metallic DES on a one-to-one ratio. With 1,800 patients, learn why reporting of 2-year data was warranted due to safety concerns. Discover when scaffold thrombosis was seen to increase and whether any relevant predictors for scaffold thrombosis were observed. What still needs to be explored in this emerging technology? Enter the discussion here…
This interview was filmed at EuroPCR 2017: see more videos here [ Ссылка ]
